Scalper1 News
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene’s (CELG) Q2 earnings rose 18% over the year-earlier quarter to 90 cents a share, beating consensus by a penny. Sales increased 17% to $1.87 billion, about $20 million above estimates. The company added $100 million to its full-year revenue Scalper1 News
Scalper1 News